PMID- 28326906
OWN - NLM
STAT- MEDLINE
DCOM- 20170807
LR  - 20170807
IS  - 1941-9260 (Electronic)
IS  - 0032-5481 (Linking)
VI  - 129
IP  - 6
DP  - 2017 Aug
TI  - A practical guide to the sublingual immunotherapy tablet adverse event profile: 
      implications for clinical practice.
PG  - 590-597
LID - 10.1080/00325481.2017.1302306 [doi]
AB  - OBJECTIVES: Treatment with allergy immunotherapy improves allergic 
      rhinoconjunctivitis, but can also improve comorbidities associated with allergic 
      rhinitis such as asthma. Sublingual immunotherapy (SLIT)-tablets are a convenient 
      and efficacious method of allergy immunotherapy. They are self-administered after 
      the first tablet has been provided under medical supervision. Therapy may elicit 
      local reactions or, rarely, systemic allergic reactions. The objective of this 
      report is to inform healthcare practitioners about the safety and tolerability 
      profile of SLIT-tablets and use this information to provide practical guidance 
      that may inform patients regarding potential adverse reactions and how to manage 
      them. METHODS: Pooled analyses of safety data from completed randomized, 
      multicenter, double-blind, placebo-controlled phase 2 and phase 3 US and EU 
      trials of timothy grass, short ragweed, and SQ house dust mite SLIT-tablets were 
      conducted to characterize safety and tolerability. RESULTS: SLIT-tablets are 
      generally well tolerated. No life-threatening events, serious systemic allergic 
      reactions, or events that compromised the airway have been reported. The most 
      common treatment-related adverse events (AEs) are oral site reactions, most of 
      which begin on day 1 of treatment, recur for less than 2 weeks, and resolve after 
      approximately 30-60 minutes. Systemic allergic reactions have been managed with 
      conventional pharmacotherapy. Reactions treated with epinephrine are uncommon, 
      but have been reported. Treatment of AEs, treatment discontinuation 
      considerations, and patient FAQs regarding SLIT-tablet safety/tolerability are 
      discussed. CONCLUSIONS: This report gives healthcare providers valuable 
      information to educate patients regarding what to expect in terms of SLIT-tablet 
      safety and tolerability. Practical guidance is also provided to ensure proper 
      treatment of any adverse reactions.
FAU - Bernstein, David I
AU  - Bernstein DI
AD  - a Bernstein Clinical Research Center and Department of Medicine and Environmental 
      Health , University of Cincinnati , Cincinnati , OH , USA.
FAU - Bardelas, Jose A Jr
AU  - Bardelas JA Jr
AD  - b Allergy and Asthma Center of North Carolina , High Point , NC , USA.
FAU - Svanholm Fogh, Bodil
AU  - Svanholm Fogh B
AD  - c ALK , Horsholm , Denmark.
FAU - Kaur, Amarjot
AU  - Kaur A
AD  - d Merck & Co., Inc. , Kenilworth , NJ , USA.
FAU - Li, Ziliang
AU  - Li Z
AD  - d Merck & Co., Inc. , Kenilworth , NJ , USA.
FAU - Nolte, Hendrik
AU  - Nolte H
AD  - d Merck & Co., Inc. , Kenilworth , NJ , USA.
LA  - eng
PT  - Clinical Trial, Phase II
PT  - Clinical Trial, Phase III
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
DEP - 20170322
PL  - England
TA  - Postgrad Med
JT  - Postgraduate medicine
JID - 0401147
RN  - 0 (Tablets)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Ambrosia
MH  - Animals
MH  - Child
MH  - Child, Preschool
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Poaceae
MH  - Pyroglyphidae
MH  - Rhinitis, Allergic/*drug therapy/*immunology
MH  - Self Care
MH  - Sublingual Immunotherapy/*adverse effects
MH  - Tablets
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Adverse events
OT  - allergy immunotherapy
OT  - clinical practice
OT  - safety
OT  - sublingual immunotherapy
OT  - tablets
EDAT- 2017/03/23 06:00
MHDA- 2017/08/08 06:00
CRDT- 2017/03/23 06:00
PHST- 2017/03/23 06:00 [pubmed]
PHST- 2017/08/08 06:00 [medline]
PHST- 2017/03/23 06:00 [entrez]
AID - 10.1080/00325481.2017.1302306 [doi]
PST - ppublish
SO  - Postgrad Med. 2017 Aug;129(6):590-597. doi: 10.1080/00325481.2017.1302306. Epub 
      2017 Mar 22.